Who is a good candidate for ChondroFiller injection?

The patients most likely to benefit from ChondroFiller injection are those with a discrete, localised area of cartilage damage — an ICRS Grade III or IV focal lesion — rather than wear spread across the whole joint surface. In practical terms, this typically means a patch of damaged cartilage up to 3 cm² in area (the primary indication), though suitable anatomy can extend that to 6 cm², surrounded by healthier cartilage on all sides. That intact border matters: it helps contain the injected collagen scaffold and provides the local cell population the scaffold needs to work with.

ChondroFiller injection is also worth considering when conventional surgical cartilage repair — such as MACI or OATS — would represent a disproportionate intervention, or when a patient cannot commit to the structured post-operative rehabilitation those procedures require. The outpatient, ultrasound-guided route is meaningful here: there is no general anaesthetic, no operating theatre, and no lengthy recovery.

It is equally important to be clear about who is outside scope. Patients with diffuse, end-stage osteoarthritis — Kellgren-Lawrence Grade IV on plain X-ray — are generally not candidates for cartilage scaffold treatment of any kind. Where joint preservation is no longer realistic, the honest conversation is about joint replacement, not regenerative injection.

Although ChondroFiller carries CE marking for use in multiple joints, including the ankle, hip, and shoulder, the evidence reviewed here focuses on focal knee cartilage defects.

What ChondroFiller injection is and how it works

Unlike cell-based procedures such as ACI or MACI, ChondroFiller injection does not require any tissue to be harvested from the patient and no laboratory work takes place before treatment. The material itself is an acellular, injectable scaffold made from Type I collagen — acid-extracted from murine tissue — that arrives ready to use in a single appointment.

Once placed into the defect under ultrasound guidance, the collagen solution polymerises within minutes on contact with the joint environment, forming a stable three-dimensional matrix that fills and temporarily occupies the damaged area. No cells are delivered at this stage; the scaffold works by what is known as matrix-induced chondrogenesis — in plain terms, it is designed to recruit the patient's own repair cells. The matrix releases chemotactic signals that draw synovial-derived progenitor cells in from the surrounding tissue. Those cells migrate into the scaffold, differentiate into chondrocytes — the specialised cells responsible for producing cartilage — and begin laying down new extracellular matrix. As this repair tissue gradually matures, the collagen scaffold biodegrades and is replaced.

The practical implication of this design is that the entire process is single-stage. There is no biopsy appointment, no weeks-long cell culture, and no second procedure to implant the result. For patients who have been told they need a two-stage cartilage operation, this distinction is clinically meaningful — though whether the injectable route is appropriate depends on the specific anatomy and defect characteristics assessed at consultation.

What the outpatient injection procedure involves

On the day of treatment, patients attend a clinic appointment rather than an operating theatre. There is no general anaesthetic — local anaesthesia or mild sedation is sufficient to keep the area comfortable — and no overnight hospital stay is required.

The injection is administered under image guidance, either ultrasound or fluoroscopy, allowing the clinician to confirm accurate placement of the collagen scaffold directly into the defect site. The procedure takes place in a fluid joint environment; the collagen solution polymerises within minutes of contact with the joint, forming the stable matrix described in the previous section. The full appointment fits within a single clinic visit.

Because no cell harvest or biopsy is involved, there is no preliminary procedure to attend and no laboratory waiting period before treatment can proceed. Patients who have previously been told they face two separate theatre operations for cartilage repair will find this a meaningful practical difference in what the treatment day actually involves.

A theatre-based route for collagen scaffold implantation exists in the surgical literature, but the outpatient pathway described here does not require that setting.

After the injection, most patients are advised to reduce loading on the treated joint for an initial period — commonly a few days to two or three weeks — before gradually returning to normal activity. The precise schedule, including any physiotherapy requirements, is confirmed at consultation, as it varies with defect site, joint, and individual factors. Recovery is generally considerably less demanding than that following open or arthroscopic cartilage surgery.

Clinical outcomes: what the evidence shows

Across four knee-specific studies reviewed for the April 2025 Clinical Evaluation Report, ChondroFiller injection produced mean IKDC score improvements of approximately 30 points — consistently exceeding the established minimum clinically important difference of 16.7 points and translating into meaningful change in daily function and activity.

The most detailed dataset comes from the Jerosch prospective post-market clinical follow-up (PMCF) study, which recorded a mean gain of 32.4 IKDC points. At three-year follow-up those gains were not only sustained but marginally increased, with patients reaching a mean IKDC score of 80 — broadly consistent with near-normal knee function.

MRI findings support the patient-reported picture. MOCART scores — the imaging measure of repair tissue quality — ranged from 81.6 to 84.3 in European cohorts, indicating greater than 80% defect fill with good peripheral integration. The trajectory matters: mean MOCART rose from 65.3 at four weeks to 81.6 at one year, confirming ongoing in vivo maturation rather than a static or immediate effect. Separate MRI assessment showed reductions in bone marrow oedema, diminished periarticular effusion, and visible joint space widening, pointing to structural reconstitution alongside a reduction in local inflammation. Consistent with that structural picture, the reported complication rate is approximately 0% and the reoperation rate 3–8% — favourably positioned relative to microfracture (up to 41% reoperation) and ACI/MACI (up to 37% reoperation rate, up to 17% complication rate).

These results derive from post-market studies rather than independent randomised controlled trials, so long-term RCT data remain pending — a characteristic of many single-stage cartilage platforms at this stage of adoption rather than a specific limitation of this dataset.

How ChondroFiller injection compares to surgical cartilage repair

Cartilage repair is not a single-pathway field, and ChondroFiller injection sits within a spectrum of techniques that each suit a distinct clinical profile.

Microfracture was historically the default for smaller defects, typically below 2 cm², because of its technical simplicity. Its reputation has declined considerably: the repair tissue it produces is fibrocartilage rather than hyaline-like cartilage, and studies consistently show deterioration at two to three years alongside damage to the subchondral bone plate that can compromise the results of any later procedure. It is no longer regarded as a modern first-line choice for most focal lesions.

ACI and MACI carry a strong long-term evidence base — particularly for larger defects in the 2–10 cm² range — but both require two separate theatre procedures: an initial biopsy, a period of laboratory cell culture, and then re-implantation under general or spinal anaesthesia. That two-stage commitment, combined with higher complication and reoperation rates relative to single-stage options, makes them most appropriate where the defect size or complexity genuinely warrants the additional resource.

OATS and mosaicplasty offer single-stage autograft transfer for defects roughly in the 1–4 cm² range, with solid structural outcomes. The principal trade-off is donor-site morbidity: harvesting osteochondral plugs from a healthy area of the same joint introduces a second injury site, and that consideration weighs against it in some patient profiles.

ChondroFiller injection occupies a different category from all three. As an ultrasound-guided outpatient procedure requiring no theatre, no general anaesthesia, and no donor tissue, it offers a non-operative pathway for suitable focal defects — including those up to 6 cm² where microfracture would be inadequate but surgical intervention may be disproportionate or unsuitable for the patient's circumstances. These are different tools designed for different clinical scenarios, not interchangeable alternatives.

Getting an assessment in London

Determining whether ChondroFiller injection is the right route begins with a specialist cartilage assessment — ideally with recent MRI available — to confirm that the lesion is focal, appropriately graded, and contained within borders suitable for an injectable scaffold approach rather than a surgical repair.

At the London Cartilage Clinic on Harley Street, that assessment is led by Professor Paul Y. F. Lee, whose specialist focus on cartilage preservation allows him to weigh the full range of options — from ultrasound-guided ChondroFiller injection through to surgical cartilage repair — and recommend the pathway most appropriate to the individual presentation.

If you would like to discuss whether ChondroFiller injection is suitable for your knee, you can book an assessment at londoncartilage.com.